U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal Type (Canine, Feline), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within Immediate
U.S. Veterinary Oncology Market Growth & Trends
The U.S. veterinary oncology market size is expected to reach USD 171.16 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.7% from 2022 to 2030. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.
For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.
In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.
For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.
U.S. Veterinary Oncology Market Report Highlights
U.S. Veterinary Oncology Market Growth & Trends
The U.S. veterinary oncology market size is expected to reach USD 171.16 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.7% from 2022 to 2030. The increasing prevalence of cancer in pets, willingness to spend on them by pet owners, and use of canines as a model for clinical trials by researchers are the key contributing factor toward the market growth. In addition, a rise in the incidence of cancer in the feline population and rising pet ownership resulting in the increased focus on pet health is further expected to spur the growth. Moreover, companies are increasingly adopting strategies, such as M&As, research agreements, collaboration, partnerships, geographic expansion, and product development to enhance their market position.
For instance, in November 2020, Virbac publicized the approval of Stelfonta, a novel intratumoral injection treatment for canine mast cell tumors. In addition, Elanco purchased Aratana Therapeutics for its pet products pipeline. The company also had an agreement to create rabacfosadine (Tanovea), a drug from VetDC. In addition, in July 2021, Elanco proclaimed that the FDA granted full approval of Tanovea for the lymphoma treatment in dogs. Hence, the market is expected to witness intense competition over the forecast period. The growing prevalence of cancer in companion animals is expected to propel the need for effective treatment options.
In canines, appendicular osteosarcoma is an extremely aggressive illness and curative-intent treatment comprises surgical resection of the tumor followed by chemotherapy to diminish the risk of tumor cells spreading to other areas, particularly the lungs. The golden retriever breed has been reported to have a high cancer prevalence compared to others. Golden Retriever is one of the favorite breeds in the U.S. and increasing concerns regarding the wellbeing of pets are contributing to the market growth. Clinical trials are a critical aspect of veterinary oncology. The accelerated number of clinical research involving surgical procedures in pets is further fueling the market growth.
For instance, in May 2019, Oregon State University conducted a research study stating that the risk of cancer recurrence reduced to 60% in dogs whose tumors were completely resected. With the growing number of pet parents in the U.S., animal health awareness is rising among people. In the U.S., various pet health awareness events are conducted to spread awareness, such as National Pet Week. The risk of animals spreading COVID-19 to individuals is considered to be little. The FDA is alert that the COVID-19 pandemic may influence the ongoing studies being conducted to provision new animal drug development. Thereby, guidelines were issued in April 2020 to help diminish the potential impact of the pandemic on new animal drug development.
U.S. Veterinary Oncology Market Report Highlights
- The radiology segment is expected to dominate the market. Factors, such as increasing government initiatives for the establishment of new veterinary radiation centers and advancements in radiation technology, are expected to boost the segment growth
- The immunotherapy segment is estimated to register the fastest CAGR from 2022 to 2030 owing to the growing number of veterinary centers focused on carrying out clinical trials in immunotherapy areas
- Chemotherapy is estimated to be the second-largest therapy segment by 2030. According to the Cancer Veterinary Center, the most common canine & feline tumors treated with chemotherapy are osteosarcomas, lymphomas, hemangiosarcoma, mast cell tumors, bladder tumors, mammary gland tumors, etc.
- The canine segment accounted for the largest revenue share in 2021. The high incidence of cancer in canines and ongoing product innovations in this domain contributed to the segment growth
- Market players are undertaking various competitive strategies to gain an edge over others. For instance, in May 2020, PetCure Oncology and Sugar Land Veterinary Specialists publicized a novel radiation oncology service, expanding their network in Houston
CHAPTER 1 RESEARCH METHODOLOGY & SCOPE
1.1 Market Segmentation & Scope
1.1.1 Segment Scope
1.1.2 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Target Population & Patient Stratification (Top-down estimation): mODEL
1.6.2 Assumptions /Key Considerations
1.6.3 Commodity Flow Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Abbreviations
1.10 Report Objectives
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.1.1 U.S. Veterinary Oncology market Outlook, 2017-2030 (USD Million)
2.2 U.S. Veterinary Oncology Market Summary, 2021
2.3 Segment Outlook
CHAPTER 3 VETERINARY ONCOLOGY MARKET VARIABLES TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping by Technology, 2021
3.3 U.S. Veterinary Oncology Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increasing prevalence of cancer in pets
3.3.1.2 Increasing R&D in pet cancer therapy
3.3.1.3 Growing focus on animal safety
3.3.1.4 Growing demand for pet insurance
3.3.1.5 Technological advancements in pet cancer treatment
3.3.1.6 Increase in pet adoption
3.3.2 Market restraint analysis
3.3.2.1 High cost of pet cancer treatments
3.3.2.2 Increasing incidence of pet abandonment and euthanasia
3.3.2.3 Adverse effects of drugs used for pet cancer treatment
3.3.3 Industry challenges
3.3.3.1 Illegal veterinary medicines
3.4 Industry Analysis - Porter’s
3.4.1 Supplier Power: Moderate
3.4.2 Buyer Power: Low to Moderate
3.4.3 Threat of Substitutes: Moderate to High
3.4.4 Threat of New entrants: Moderate
3.4.5 Competitive Rivalary: High
3.5 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
3.5.1 Political and Legal landscape
3.5.2 Economic Landscape
3.5.3 Technology Landscape
3.5.4 Social Landscape
3.6 User Perspective Analysis
3.6.1 List of Key End Users
3.6.2 Consumer behavior
3.6.3 Market Influencer Analysis
3.7 Regulatory Framework
3.7.1 Regulatory Landscape
3.7.2 Standards & compliances
3.8 Technology Overview
3.8.1 Technology timeline analysis
3.9 Product Pipeline Analysis
3.10 Pricing Trend Analysis
CHAPTER 4 COVID-19 IMPACT
4.1 Covid-19 Prevalence
4.2 Impact of COVID-19 on the Market
4.3 Regulatory/Policy Changes
4.4 Strategies Adopted by Market Players
CHAPTER 5 COMPETITIVE ANALYSIS
5.1 Market Participation Categorization
5.2 Competitive Analysis
5.2.1 Company market position analysis
5.2.2 Market leader
5.2.3 Innovators
5.3 Market Entry Strategies
CHAPTER 6 U.S. VETERINARY ONCOLOGY MARKET: THERAPY ESTIMATES & TREND ANALYSIS
6.1 Therapy Market Share Analysis, 2021 & 2030
6.2 Therapy Dashboard
6.3 Surgery
6.3.1 Surgery market estimates and forecasts, 2017 - 2030 (USD Million)
6.4 Radiology
6.4.1 Radiology market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2 Stereotactic Radiation Therapy
6.4.2.1 Stereotactic radiation therapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.2 Gamma knife
6.4.2.2.1 Gamma Knife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.3 Linear accelerators
6.4.2.3.1 LINAC market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.4 Particle beam
6.4.2.4.1 PBRT market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.5 Cyberknife
6.4.2.5.1 CyberKnife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.3 Brachytherapy
6.4.3.1 Brachytherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.4 Others
6.4.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
6.5 Chemotherapy
6.5.1 Chemotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.6 Immunotherapy
6.6.1 Immunotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.7 Others
6.7.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 U.S. VETERINARY ONCOLOGY MARKET: ANIMAL TYPE ESTIMATES & TREND ANALYSIS
7.1 Animal Type Market Share Analysis, 2021 & 2030
7.2 Animal Type Dashboard
7.3 Canine
7.3.1 Canine market estimates and forecasts, 2017 - 2030 (USD million)
7.3.2 Lymphoma
7.3.2.1 Lymphoma market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.3 Mast Cell Cancer
7.3.3.1 Mast Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.4 Mammary and Squamous Cell Cancer
7.3.4.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.5 Others
7.3.5.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.4 Feline
7.4.1 Feline market estimates and forecasts, 2017 - 2030 (USD million)
7.4.2 Mammary and Squamous Cell Cancer
7.4.2.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.3 Others
7.4.3.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.5 Others
7.5.1 Others market estimates and forecasts, 2017 - 2030 (USD million)
CHAPTER 8 COMPANY PROFILES
8.1 Zoetis
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Boehringer Ingelheim GmbH
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Elanco
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 PetCure Oncology
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Accuray Incorporated
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Varian Medical Systems, Inc.
8.6.1 Company overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Morphogenesis, Inc.
8.7.1 Company overview
8.7.2 Product benchmarking
8.7.3 Strategic initiatives
8.8 Karyopharm Therapeutics, Inc.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Regeneus Ltd.
8.9.1 Company Overview
8.9.2 Product Benchmarking
8.9.3 Strategic Initiatives
8.10 OHC (One Health Company)
8.10.1 Company overview
8.10.2 Product benchmarking
8.10.3 Strategic initiatives
8.11 List of Market Participants
1.1 Market Segmentation & Scope
1.1.1 Segment Scope
1.1.2 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s Internal Database
1.3.3 Secondary sources
1.3.4 Primary Research:
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Target Population & Patient Stratification (Top-down estimation): mODEL
1.6.2 Assumptions /Key Considerations
1.6.3 Commodity Flow Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 Abbreviations
1.10 Report Objectives
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
2.1.1 U.S. Veterinary Oncology market Outlook, 2017-2030 (USD Million)
2.2 U.S. Veterinary Oncology Market Summary, 2021
2.3 Segment Outlook
CHAPTER 3 VETERINARY ONCOLOGY MARKET VARIABLES TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Ancillary market outlook
3.2 Penetration & Growth Prospect Mapping by Technology, 2021
3.3 U.S. Veterinary Oncology Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increasing prevalence of cancer in pets
3.3.1.2 Increasing R&D in pet cancer therapy
3.3.1.3 Growing focus on animal safety
3.3.1.4 Growing demand for pet insurance
3.3.1.5 Technological advancements in pet cancer treatment
3.3.1.6 Increase in pet adoption
3.3.2 Market restraint analysis
3.3.2.1 High cost of pet cancer treatments
3.3.2.2 Increasing incidence of pet abandonment and euthanasia
3.3.2.3 Adverse effects of drugs used for pet cancer treatment
3.3.3 Industry challenges
3.3.3.1 Illegal veterinary medicines
3.4 Industry Analysis - Porter’s
3.4.1 Supplier Power: Moderate
3.4.2 Buyer Power: Low to Moderate
3.4.3 Threat of Substitutes: Moderate to High
3.4.4 Threat of New entrants: Moderate
3.4.5 Competitive Rivalary: High
3.5 U.S. Veterinary Oncology - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
3.5.1 Political and Legal landscape
3.5.2 Economic Landscape
3.5.3 Technology Landscape
3.5.4 Social Landscape
3.6 User Perspective Analysis
3.6.1 List of Key End Users
3.6.2 Consumer behavior
3.6.3 Market Influencer Analysis
3.7 Regulatory Framework
3.7.1 Regulatory Landscape
3.7.2 Standards & compliances
3.8 Technology Overview
3.8.1 Technology timeline analysis
3.9 Product Pipeline Analysis
3.10 Pricing Trend Analysis
CHAPTER 4 COVID-19 IMPACT
4.1 Covid-19 Prevalence
4.2 Impact of COVID-19 on the Market
4.3 Regulatory/Policy Changes
4.4 Strategies Adopted by Market Players
CHAPTER 5 COMPETITIVE ANALYSIS
5.1 Market Participation Categorization
5.2 Competitive Analysis
5.2.1 Company market position analysis
5.2.2 Market leader
5.2.3 Innovators
5.3 Market Entry Strategies
CHAPTER 6 U.S. VETERINARY ONCOLOGY MARKET: THERAPY ESTIMATES & TREND ANALYSIS
6.1 Therapy Market Share Analysis, 2021 & 2030
6.2 Therapy Dashboard
6.3 Surgery
6.3.1 Surgery market estimates and forecasts, 2017 - 2030 (USD Million)
6.4 Radiology
6.4.1 Radiology market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2 Stereotactic Radiation Therapy
6.4.2.1 Stereotactic radiation therapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.2 Gamma knife
6.4.2.2.1 Gamma Knife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.3 Linear accelerators
6.4.2.3.1 LINAC market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.4 Particle beam
6.4.2.4.1 PBRT market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.2.5 Cyberknife
6.4.2.5.1 CyberKnife market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.3 Brachytherapy
6.4.3.1 Brachytherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.4.4 Others
6.4.4.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
6.5 Chemotherapy
6.5.1 Chemotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.6 Immunotherapy
6.6.1 Immunotherapy market estimates and forecasts, 2017 - 2030 (USD Million)
6.7 Others
6.7.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
CHAPTER 7 U.S. VETERINARY ONCOLOGY MARKET: ANIMAL TYPE ESTIMATES & TREND ANALYSIS
7.1 Animal Type Market Share Analysis, 2021 & 2030
7.2 Animal Type Dashboard
7.3 Canine
7.3.1 Canine market estimates and forecasts, 2017 - 2030 (USD million)
7.3.2 Lymphoma
7.3.2.1 Lymphoma market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.3 Mast Cell Cancer
7.3.3.1 Mast Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.4 Mammary and Squamous Cell Cancer
7.3.4.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.3.5 Others
7.3.5.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.4 Feline
7.4.1 Feline market estimates and forecasts, 2017 - 2030 (USD million)
7.4.2 Mammary and Squamous Cell Cancer
7.4.2.1 Mammary and Squamous Cell Cancer market estimates and forecasts, 2017 - 2030 (USD Million)
7.4.3 Others
7.4.3.1 Others market estimates and forecasts, 2017 - 2030 (USD Million)
7.5 Others
7.5.1 Others market estimates and forecasts, 2017 - 2030 (USD million)
CHAPTER 8 COMPANY PROFILES
8.1 Zoetis
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Boehringer Ingelheim GmbH
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 Elanco
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 PetCure Oncology
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Accuray Incorporated
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.5.4 Strategic Initiatives
8.6 Varian Medical Systems, Inc.
8.6.1 Company overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Morphogenesis, Inc.
8.7.1 Company overview
8.7.2 Product benchmarking
8.7.3 Strategic initiatives
8.8 Karyopharm Therapeutics, Inc.
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Regeneus Ltd.
8.9.1 Company Overview
8.9.2 Product Benchmarking
8.9.3 Strategic Initiatives
8.10 OHC (One Health Company)
8.10.1 Company overview
8.10.2 Product benchmarking
8.10.3 Strategic initiatives
8.11 List of Market Participants
LIST OF TABLES
Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. U.S. Pet Ownership, 2019 - 2020 (Millions)
Table 4. U.S. Pet Expenditure, 2019 - 2020 (USD)
Table 5. Clinical Trials in progress for companion animals by UC Davis in 2018
Table 6. U.S. Veterinary Oncology Market, 2017 - 2030 (USD Million)
Table 7. U.S. Veterinary Oncology Market, by therapy, 2017 - 2030 (USD Million)
Table 8. U.S. Veterinary radiology Market, by type, 2017 - 2030 (USD Million)
Table 9. U.S. Veterinary stereotactic radiation therapy Market, by type, 2017 - 2030 (USD Million)
Table 10. U.S. Veterinary Oncology Market, by animal type, 2017 - 2030 (USD Million)
Table 11. U.S. feline oncology Market by cancer type, 2017 - 2030 (USD Million)
Table 12. U.S. canine oncology Market by cancer type, 2017 - 2030 (USD Million)
Table 1. List of secondary sources
Table 2. List of abbreviation
Table 3. U.S. Pet Ownership, 2019 - 2020 (Millions)
Table 4. U.S. Pet Expenditure, 2019 - 2020 (USD)
Table 5. Clinical Trials in progress for companion animals by UC Davis in 2018
Table 6. U.S. Veterinary Oncology Market, 2017 - 2030 (USD Million)
Table 7. U.S. Veterinary Oncology Market, by therapy, 2017 - 2030 (USD Million)
Table 8. U.S. Veterinary radiology Market, by type, 2017 - 2030 (USD Million)
Table 9. U.S. Veterinary stereotactic radiation therapy Market, by type, 2017 - 2030 (USD Million)
Table 10. U.S. Veterinary Oncology Market, by animal type, 2017 - 2030 (USD Million)
Table 11. U.S. feline oncology Market by cancer type, 2017 - 2030 (USD Million)
Table 12. U.S. canine oncology Market by cancer type, 2017 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Target Population & Treatment Rate
Fig. 10 Treatment Cost analysis
Fig. 11 Commodity flow analysis
Fig. 12 U.S. Veterinary Oncology market revenue (USD Million)
Fig. 13 U.S. Veterinary Oncology Market Snapshot
Fig. 14 Segment Outlook, 2021
Fig. 15 Parent market outlook
Fig. 16 Ancillary market outlook
Fig. 17 Penetration &growth prospect mapping by Technology, 2021
Fig. 18 U.S. Veterinary Oncology market dynamics
Fig. 19 U.S. Veterinary Oncology market driver impact
Fig. 20 Total pet expenditure in the U.S., 2010 - 2019, Billion
Fig. 21 Estimated pet population in the U.S., 2015 - 2019, Million
Fig. 22 U.S. Veterinary Oncology market restraint impact
Fig. 23 Consumer behavior analysis
Fig. 24 Market influencing analysis
Fig. 25 Technology timeline analysis
Fig. 26 Covid - 19 prevalence
Fig. 27 Market participant categorization
Fig. 28 Veterinary oncology company market position analysis
Fig. 29 Market entry strategies
Fig. 30 U.S. Veterinary Oncology market: Therapy movement analysis
Fig. 31 U.S. Veterinary Oncology Market: Therapy Dashboard
Fig. 32 Surgery market, 2017 - 2030 (USD Million)
Fig. 33 Radiology market, 2017 - 2030 (USD Million)
Fig. 34 Veterinary Stereotactic radiation therapy market, 2017 - 2030 (USD Mullion)
Fig. 35 Gamma knife market revenues, 2017 - 2030 (USD Million)
Fig. 36 LINAC market revenues, 2017 - 2030 (USD Million)
Fig. 37 PBRT market revenues, 2017 - 2030 (USD Million)
Fig. 38 CyberKnife market revenues, 2017 - 2030 (USD Million)
Fig. 39 Brachytherapy market, 2017 - 2030 (USD Mullion)
Fig. 40 Others market, 2017 - 2030 (USD Mullion)
Fig. 41 Chemotherapy market, 2017 - 2030 (USD Million)
Fig. 42 Immunotherapy market, 2017 - 2030 (USD Million)
Fig. 43 Others market, 2017 - 2030 (USD Million)
Fig. 44 U.S. Veterinary Oncology market: Animal Type movement analysis
Fig. 45 U.S. Veterinary Oncology Market: Animal Type Dashboard
Fig. 46 Canine market, 2017 - 2030 (USD Million)
Fig. 47 Lymphoma market, 2017 - 2030 (USD Million)
Fig. 48 Mast cell cancer market, 2017 - 2030 (USD Million)
Fig. 49 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 50 Others market, 2017 - 2030 (USD Million)
Fig. 51 Feline market, 2017 - 2030 (USD Million)
Fig. 52 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 53 Others market, 2017 - 2030 (USD Million)
Fig. 54 Others market, 2017 - 2030 (USD Million)
Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value - chain - based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Target Population & Treatment Rate
Fig. 10 Treatment Cost analysis
Fig. 11 Commodity flow analysis
Fig. 12 U.S. Veterinary Oncology market revenue (USD Million)
Fig. 13 U.S. Veterinary Oncology Market Snapshot
Fig. 14 Segment Outlook, 2021
Fig. 15 Parent market outlook
Fig. 16 Ancillary market outlook
Fig. 17 Penetration &growth prospect mapping by Technology, 2021
Fig. 18 U.S. Veterinary Oncology market dynamics
Fig. 19 U.S. Veterinary Oncology market driver impact
Fig. 20 Total pet expenditure in the U.S., 2010 - 2019, Billion
Fig. 21 Estimated pet population in the U.S., 2015 - 2019, Million
Fig. 22 U.S. Veterinary Oncology market restraint impact
Fig. 23 Consumer behavior analysis
Fig. 24 Market influencing analysis
Fig. 25 Technology timeline analysis
Fig. 26 Covid - 19 prevalence
Fig. 27 Market participant categorization
Fig. 28 Veterinary oncology company market position analysis
Fig. 29 Market entry strategies
Fig. 30 U.S. Veterinary Oncology market: Therapy movement analysis
Fig. 31 U.S. Veterinary Oncology Market: Therapy Dashboard
Fig. 32 Surgery market, 2017 - 2030 (USD Million)
Fig. 33 Radiology market, 2017 - 2030 (USD Million)
Fig. 34 Veterinary Stereotactic radiation therapy market, 2017 - 2030 (USD Mullion)
Fig. 35 Gamma knife market revenues, 2017 - 2030 (USD Million)
Fig. 36 LINAC market revenues, 2017 - 2030 (USD Million)
Fig. 37 PBRT market revenues, 2017 - 2030 (USD Million)
Fig. 38 CyberKnife market revenues, 2017 - 2030 (USD Million)
Fig. 39 Brachytherapy market, 2017 - 2030 (USD Mullion)
Fig. 40 Others market, 2017 - 2030 (USD Mullion)
Fig. 41 Chemotherapy market, 2017 - 2030 (USD Million)
Fig. 42 Immunotherapy market, 2017 - 2030 (USD Million)
Fig. 43 Others market, 2017 - 2030 (USD Million)
Fig. 44 U.S. Veterinary Oncology market: Animal Type movement analysis
Fig. 45 U.S. Veterinary Oncology Market: Animal Type Dashboard
Fig. 46 Canine market, 2017 - 2030 (USD Million)
Fig. 47 Lymphoma market, 2017 - 2030 (USD Million)
Fig. 48 Mast cell cancer market, 2017 - 2030 (USD Million)
Fig. 49 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 50 Others market, 2017 - 2030 (USD Million)
Fig. 51 Feline market, 2017 - 2030 (USD Million)
Fig. 52 Mammary and squamous cell cancer market, 2017 - 2030 (USD Million)
Fig. 53 Others market, 2017 - 2030 (USD Million)
Fig. 54 Others market, 2017 - 2030 (USD Million)
